Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.
about
Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.HIV Infection and Acute Stroke: A Case Report and a Review of the Literature.Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Systemic effects of inflammation on health during chronic HIV infectionIn vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovirEffects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.Chronic HIV disease and activation of the coagulation systemInflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.T cell activation predicts carotid artery stiffness among HIV-infected womenUsing the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities.Adiponectin and interleukin-6, but not adipose tissue, are associated with worse neurocognitive function in HIV-infected menAbacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclaseElevated Biomarkers of Inflammation and Coagulation in Patients with HIV Are Associated with Higher Framingham and VACS Risk Index Scores.HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levelsD-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events.Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working GroupA randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infectionCardiovascular disease in HIV infection.Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimensInflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy.Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women.HIV Infection and Carotid Artery Intima-media Thickness: Pooled Analyses Across 5 Cohorts of the NHLBI HIV-CVD Collaborative.HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generationAssociations between antiretroviral use and subclinical coronary atherosclerosis.Coronary artery disease in patients with HIV infection.Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population.Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors.Can Biomarkers Advance HIV Research and Care in the ART Era?Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.Higher Art Adherence is Associated with Lower Systemic Inflammation in Treatment-Naïve Ugandans Who Achieve Virologic Suppression.
P2860
Q28543075-A549AD9F-E217-4EC9-8759-BB74EF983304Q30248286-CC51DAE2-66BD-4137-BF04-6ACBD975449EQ30670446-7BE1B67D-B46D-4158-A445-F2743FB20F53Q31118978-0D77736B-C0AB-4134-B3C0-8D966286696BQ33577551-0B91A0ED-D05B-4D8B-8788-FA0931268B57Q33749579-AB80F66F-0EBC-499A-A35C-652AE33D5E4AQ33812049-1B6F1C5F-88F0-4441-B0A1-E30C33944096Q34157856-FBF2D0FC-3267-41BE-A759-DB7205126A0FQ34342368-307A6AF7-B433-460A-ACD1-B4FBC476F2DCQ34796153-E139D1AF-0010-4DEB-B764-09EF1F4D5EC1Q35009269-F4B60A0B-5AFE-42D9-BFCB-833CEBB29AFDQ35113323-BF93B411-FF4F-48E8-9088-24F26823FA21Q35204909-7DDCCEBF-E070-4928-B57B-B60D2D5C3A73Q35587294-35BBFE6A-DDDF-4745-927E-5C2350256AAEQ35737682-F8F4F166-55AB-4714-A570-7D7DD276F69FQ35862321-556F97CA-1FCA-4240-B4C4-3142B5617E47Q35958319-60A22A0D-F27B-4216-9122-6AEE5E3E6600Q35992200-56DE3814-D7E7-43CA-8992-8BC4F92F61CBQ36104762-2B6373B6-56B0-4482-AACF-70C7B0978EFEQ36116238-213101C3-EF7A-4237-AEDF-FCB41EBC85E0Q36147395-75D9435D-92A6-48A1-97AC-615C8A3A9B59Q36346646-0BA98A6B-38C5-4A27-82FC-966EF1DDE36BQ36379299-AD6AE87F-E811-469D-9C3F-3F62B108A8F2Q36408675-AB4E88C3-55C2-4E30-9ACA-9BF8DE995BBFQ36419549-FB352AB3-DB52-4C28-8817-2510CCABCBC1Q36578046-4AF833D7-EA9B-4D9F-9900-96F2C96B1F70Q36775142-02ADAFD9-0CBC-4512-A490-B6E823F5A13BQ36996000-C2B37161-EC21-4918-9E4F-0DD55E4DD8E9Q37055020-8EB5A02E-4F53-4DFB-9590-062F6FEC3C5CQ37310421-90DD5AB3-4118-4A05-8C54-134530F6BB21Q37520935-8D2944C9-42B2-423F-B3FC-07DF2763A7FAQ38352065-7B1F5932-E377-4537-A771-2BAD5AA67318Q39359637-9BD3495C-FA1C-4D5E-B0D1-4E876159AC14Q40070894-9503C560-9F8E-41FF-A67B-DCA7C1D4510AQ41257300-2AF5C29F-5777-4956-BA90-6662554CA345Q42609996-4A785B1E-BFF1-477D-B7DA-088D4736BC18Q43410386-845440AA-A43E-4876-A2C2-446BEF40568EQ46442340-DBB9F969-44F9-4362-A786-8A9ABCF83566Q47199601-EA32A5DD-3702-4E17-83EB-C5FD5A4E54A1Q47551904-0B2BE96C-9FAD-4D03-9BF3-CB142718AA25
P2860
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Inflammatory biomarkers and ab ...... Multicenter AIDS Cohort Study.
@ast
Inflammatory biomarkers and ab ...... Multicenter AIDS Cohort Study.
@en
type
label
Inflammatory biomarkers and ab ...... Multicenter AIDS Cohort Study.
@ast
Inflammatory biomarkers and ab ...... Multicenter AIDS Cohort Study.
@en
prefLabel
Inflammatory biomarkers and ab ...... Multicenter AIDS Cohort Study.
@ast
Inflammatory biomarkers and ab ...... Multicenter AIDS Cohort Study.
@en
P2093
P2860
P921
P1433
P1476
Inflammatory biomarkers and ab ...... Multicenter AIDS Cohort Study.
@en
P2093
Alan L Landay
Frank J Palella
Lisa Jacobson
Lorie Benning
Richard Elion
Robert C Kaplan
Russell P Tracy
P2860
P304
P356
10.1097/QAD.0B013E3283389DFA
P407
P577
2010-07-01T00:00:00Z